ESNA Conference and Exhibition | November 5-7, 2019 in San Diego, California

Registration will open July 15th

Speaker Information

Dr. Patrick Soon-Shiong

Chairman and Chief Executive Officer
NantWorks, LLC

Dr. Patrick Soon-ShiongPatrick Soon-Shiong, M.D., a physician, surgeon, scientist, inventor, technologist and philanthropist, has devoted his career to understanding the fundamental biology driving life-threatening diseases and translating these insights into medical innovations with global impact.

He currently serves as Chairman and Chief Executive Officer (CEO) of NantWorks, LLC. a holding company devoted to the transformation of healthcare and utilizing artificial intelligence to win the war against cancer and Alzheimer’s disease – two of the most serious diseases affecting the aging population.

Over the course of Dr. Soon-Shiong’s career, he has pioneered novel therapies for both diabetes and cancer, including the revolutionary drug Abraxane, which has received U.S. Food and Drug Administration (FDA) approval for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer in both the U.S. and E.U., published more than 100 scientific papers, and has been granted more than 230 patents worldwide for groundbreaking advancements spanning myriad fields of technology and medicine.

As a surgeon, Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig-to-man islet cell transplant in patients with diabetes.

Dr. Soon-Shiong’s path to cancer research began while doing research for the National Aeronautics and Space Administration (NASA) that involved harnessing stem cells to make insulin. In 1991, he founded a biotechnology company to develop a novel nanoparticle anti-cancer drug with the concept of using “the tumors biology against itself.”

From 1996 to 2010, Dr. Soon-Shiong served as Founder, Chairman and CEO of two global pharmaceutical companies: American Pharmaceutical Partners and Abraxis BioScience. It was during Dr. Soon-Shiong’s tenure at Abraxis that the company manufactured the world’s first protein nanoparticle drug for breast, lung and pancreatic cancer—Abraxane. In 2008, Dr. Soon-Shiong sold American Pharmaceutical Partners to Fresenius for approximately $4.6 billion and in 2010, sold Abraxis BioScience to Celgene for approximately $3.8 billion.

Following the sale of these two companies, Dr. Soon-Shiong established NantWorks, LLC, an ecosystem of companies with deep understandings in a wide variety of complex industries, from science to data, communication and mobility. Under the NantWorks umbrella, Soon-Shiong currently serves as Chairman and CEO of NantKwest, a Nasdaq-listed immunotherapy company focusing on natural killer cells, and Chairman and CEO of NantHealth, a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. When NantKwest went public in 2015, it was the largest biotech IPO by market valuation in history.

In January 2016, Dr. Soon-Shiong announced the formation of Cancer Breakthroughs 2020, a comprehensive collaboration of researchers, insurers, academic institutions and pharmaceutical companies to accelerate the potential of combination immunotherapy in the treatment of cancer.

Return to Agenda